Drug Type Bispecific antibody |
Synonyms- |
Target |
Mechanism ETA antagonists(Endothelin receptor type A antagonists), TGF-β inhibitors(Transforming growth factor beta inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic Nephropathies | Phase 2 | CN | 07 Sep 2021 | |
Pulmonary Arterial Hypertension | Preclinical | CN | 30 Jan 2022 | |
Pulmonary Fibrosis | Preclinical | CN | 30 Jan 2022 |